Strata Skin Sciences Inc (NASDAQ:SSKN) had a decrease of 0.72% in short interest. SSKN’s SI was 220,900 shares in May as released by FINRA. Its down 0.72% from 222,500 shares previously. With 22,700 avg volume, 10 days are for Strata Skin Sciences Inc (NASDAQ:SSKN)’s short sellers to cover SSKN’s short positions. The stock decreased 7.45% or $0.127 during the last trading session, reaching $1.583. About 113,240 shares traded. STRATA Skin Sciences, Inc. (NASDAQ:SSKN) has declined 59.73% since May 16, 2017 and is downtrending. It has underperformed by 71.28% the S&P500.
The stock of CymaBay Therapeutics, Inc. (NASDAQ:CBAY) is a huge mover today! The stock increased 4.96% or $0.5832 during the last trading session, reaching $12.3432. About 675,295 shares traded. CymaBay Therapeutics, Inc. (NASDAQ:CBAY) has risen 197.77% since May 16, 2017 and is uptrending. It has outperformed by 186.22% the S&P500.The move comes after 9 months positive chart setup for the $725.40 million company. It was reported on May, 16 by Barchart.com. We have $13.33 PT which if reached, will make NASDAQ:CBAY worth $58.03 million more.
STRATA Skin Sciences, Inc., a medical technology company, engages in developing and commercializing products for the treatment of dermatological disorders. The company has market cap of $7.55 million. The Company’s products include XTRAC and VTRAC devices used for the treatment of psoriasis, vitiligo, and other skin disorders; and MelaFind system, an instrument for aiding dermatologists in the evaluation of clinically atypical pigmented skin lesions, when a dermatologist chooses to obtain additional information before making a final decision to biopsy in order to rule out melanoma. It currently has negative earnings. The firm was formerly known as MELA Sciences, Inc. and changed its name to STRATA Skin Sciences, Inc. in December 2015.
More notable recent CymaBay Therapeutics, Inc. (NASDAQ:CBAY) news were published by: Seekingalpha.com which released: “CymaBay Makes Progress With Seladelpar” on April 30, 2018, also Streetinsider.com with their article: “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” published on May 15, 2018, Nasdaq.com published: “CymaBay Therapeutics Announces the Initiation of a Phase 2b Study of Seladelpar in Patients with Non-Alcoholic …” on May 08, 2018. More interesting news about CymaBay Therapeutics, Inc. (NASDAQ:CBAY) were released by: Globenewswire.com and their article: “CymaBay to Report First Quarter 2018 Financial Results on Tuesday, May 8” published on May 01, 2018 as well as Nasdaq.com‘s news article titled: “Report: Developing Opportunities within CymaBay Therapeutics, IAC/InterActiveCorp, Axcelis Technologies, La Quinta …” with publication date: April 20, 2018.
Analysts await CymaBay Therapeutics, Inc. (NASDAQ:CBAY) to report earnings on August, 9. They expect $-0.23 earnings per share, up 25.81% or $0.08 from last year’s $-0.31 per share. After $-0.32 actual earnings per share reported by CymaBay Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -28.13% EPS growth.